Following the company’s first quarter results, Roth MKM analyst Bill Kirk says there was improvement, but ultimately remains on the fence when it comes to Aurora Cannabis (Aurora Cannabis Stock Quote, Chart, News, Analysts, Financials TSX:ACB).
On August 7, ACB reported its Q1, 2025 results. The company post Adjusted EBITDA of $4.9-million on revenue of $83.4-million, a topline that was up 12%, year-over-year.
“This was a milestone quarter for Aurora, as we delivered strong net revenue1 growth, a substantial increase in adjusted EBITDA1, and positive free cash flow1,” CEO Miguel Martin said. “Our impressive performance was driven by record net revenue1 in the rapidly growing global medical cannabis segment, and we look forward to building on our achievements in key markets such as Germany, Australia, and the UK throughout fiscal 2025 and beyond. The quarter was further supported by a record contribution…
